Somewhat Positive News Coverage Somewhat Unlikely to Affect Denali Therapeutics (DNLI) Share Price

News coverage about Denali Therapeutics (NASDAQ:DNLI) has trended somewhat positive on Thursday, according to Accern Sentiment. The research firm identifies positive and negative news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Denali Therapeutics earned a news sentiment score of 0.02 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.1952534590918 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Shares of DNLI opened at $19.47 on Thursday. The firm has a market cap of $1.77 billion and a PE ratio of -3.31.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Monday, March 19th. The company reported ($0.74) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.47). analysts forecast that Denali Therapeutics will post -0.56 earnings per share for the current fiscal year.

Several brokerages recently issued reports on DNLI. Zacks Investment Research upgraded shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a research report on Tuesday, April 3rd. ValuEngine upgraded shares of Denali Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $23.25.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company's lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson's disease.

Insider Buying and Selling by Quarter for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply